Regeneron Pharmaceuticals (REGN) Current Deferred Revenue (2009 - 2026)

Regeneron Pharmaceuticals has reported Current Deferred Revenue for 18 years, with the latest figure at $684.8 million in Q2 2026.

• On a quarterly basis, Current Deferred Revenue rose 42.1% year-over-year to $684.8 million in Q2 2026; TTM through Jun 2026 was $684.8 million, a 42.1% increase from a year earlier, with the FY2025 full-year figure at $553.0 million, down 11.9% from the prior year.
• Current Deferred Revenue was $684.8 million for Q2 2026 at Regeneron Pharmaceuticals, up from $636.2 million in the prior quarter.
• The five-year high for Current Deferred Revenue was $684.8 million in Q2 2026, with the low at $381.1 million in Q2 2023.
• Average Current Deferred Revenue over 5 years is $535.8 million, with a median of $546.4 million recorded in 2022.
• The sharpest annual moves came in 2023 and 2024: Current Deferred Revenue tumbled 32.7% in 2023, then soared 53.77% in 2024.
• Over 5 years, Current Deferred Revenue stood at $477.9 million in 2022, then retreated by 3.98% to $458.9 million in 2023, then soared by 36.78% to $627.7 million in 2024, then retreated by 11.9% to $553.0 million in 2025, then rose by 23.83% to $684.8 million in 2026.
• The last three Current Deferred Revenue figures came in at $684.8 million (Q2 2026), $636.2 million (Q1 2026), and $553.0 million (Q4 2025), per Business Quant data.